



**AWTTC**

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund  
Medicines Recommended by NICE and AWMSG  
Health Board Formulary Status  
(From 01 April 2023 to 31 March 2024)



## BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable, and certainly within 60 calendar days of the publication of the decision. Commencement of the 60 days is the date known as the 'NTF start date'. For National Institute for Health and Care Excellence (NICE) recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD)/Final Draft Guideline (FDG), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For All Wales Medicines Strategy Group (AWMSG) recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60-day timescale may be delayed. In such circumstances the 'NTF start date' aligns with the date that the delaying reason has been resolved. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, The New Treatment Fund – Access to medicines recommended by NICE and AWMSG (WHC [2017] 001). From May 2024 these directions are further revised to enable the granting, in specific circumstances, of an extension to the standard 60-day timescale. This is detailed at:-

<https://www.gov.wales/directions-new-treatment-fund-exemptions>.

A formulary is an official list of medicines which may be prescribed within the health board or NHS trust to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use. Velindre University NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended over a 12-month period, commencing at least 14 months prior to the publication of this report. This is to account for the generally applicable 60-day period available to health boards and NHS trust to add these medicines to their formularies. Where an extended timescale has been authorised the data reporting system has been adapted to accommodate the variations.

## SOURCE OF INFORMATION

This report has been compiled through an analysis of health board and trust submitted data to the All Wales Therapeutics and Toxicology Centre (AWTTC).

In exceptional circumstances some medicines data have been removed from this report in light of specific factors outside the control of health boards and NHS trust.

Data extracted 31/07/2024






Key		On formulary within required timescale		On formulary outside of required timescale		Not on formulary but within required timescale
		Not on formulary and outside of required timescale		Not applicable to Velindre		

Table 1. Formulary status for New Treatment Fund medicines

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID3962 (TA882)	Voclosporin	Lupus nephritis	06 Apr 23								
ID3890 (TA890)	Difelikefalin	Pruritus	17 Apr 23								
ID3860 (TA891)	Ibrutinib	Leukaemia	21 Apr 23								
ID3860 (TA891)	Venetoclax	Leukaemia	21 Apr 23								
ID4057 (TA897)	Daratumumab	Multiple myeloma	24 Apr 23								
ID1494 (TA893)	Brexucabtagene autoleucl	Leukaemia	27 Apr 23								
ID1684 (TA895)	Axicabtagene ciloleucl	Lymphoma	27 Apr 23								
ID3893 (TA886)	Olaparib	Breast cancer	02 May 23								
ID3851 (TA898)	Trametinib	Lung cancer	11 May 23								
ID3732 (TA896)	Bulevirtide	Hepatitis D	15 May 23								
ID1648 (TA902)	Dapagliflozin	Heart failure	18 May 23								
ID3811 (TA904)	Lenvatinib	Endometrial cancer	18 May 23								
ID3811 (TA904)	Pembrolizumab	Endometrial cancer	18 May 23								
ID4027 (TA905)	Upadacitinib	Crohns disease	18 May 23								
ID3971 (TA903)	Darolutamide	Prostate cancer	19 May 23								
ID6275 (TA906)	Rimegepant	Migraine	31 May 23								
ID3788 (TA908)	Olaparib	Ovarian or fallopian tube or peritoneal cancer	08 Jun 23								
ID3851 (TA898)	Dabrafenib	Lung cancer	22 Jun 23								
ID4036 (TA914)	Pembrolizumab	Endometrial, biliary, colorectal, gastric or small intestine cancer	17 Aug 23								
ID3771 (TA912)	Cipaglucosidase alfa	Pompe disease	18 Aug 23								
ID3771 (TA912)	Miglustat	Pompe disease	18 Aug 23								
ID3859 (TA907)	Deucravacitinib	Plaque psoriasis	25 Aug 23								
ID3904 (TA915)	Pegunigalsidase alfa	Fabry disease	01 Sept 23								
ID4009 (TA916)	Bimekizumab	Arthritis	07 Sept 23								
ID6245 (TA918)	Bimekizumab	Axial spondyloarthritis	07 Sept 23								
ID3850 (TA875)	Semaglutide	Overweight and obesity	12 Sept 23								
ID1539 (TA919)	Rimegepant	Migraine	14 Sept 23								
ID3774 (TA922)	Daridorexant	Insomnia	15 Sept 23								
ID3865 (TA920)	Tofacitinib	Ankylosing spondylitis	15 Sept 23								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morganwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID1505 (HST28)	Birch bark extract	Skin wounds	20 Sept 23								
ID3973 (TA925)	Mirikizumab	Ulcerative colitis	22 Sept 23								
ID4014 (TA917)	Daratumumab	Multiple myeloma	22 Sept 23								
ID4014 (TA917)	Dexamethasone	Multiple myeloma	22 Sept 23								
ID4014 (TA917)	Lenalidomide	Multiple myeloma	22 Sept 23								
ID3945 (TA929)	Empagliflozin	Heart failure	05 Oct 23								
ID4056 (TA911)	Selpercatinib	Lung cancer	12 Oct 23								
ID3986 (TA888)	Risankizumab	Crohn's disease	16 Oct 23								
ID5078 (TA931)	Zanubrutinib	Lymphocytic leukaemia	19 Oct 23								
ID3970 (TA927)	Glofitamab	Lymphoma	20 Oct 23								
ID5106 (TA921)	Ruxolitinib	Polycythaemia vera	02 Nov 23								
ID3928 (TA913)	Mavacamten	Cardiomyopathy	06 Nov 23								
ID6279 (TA939)	Pembrolizumab	Cervical cancer	09 Nov 23								
ID800 (HST29)	Velmanase alfa	Alpha-mannosidosis	09 Nov 23								
ID6131 (TA942)	Empagliflozin	Kidney disease	17 Nov 23								
ID3995 (HST30)	Sebelipase alfa	Wolman disease	01 Dec 23								
ID4066 (TA946)	Bevacizumab	Ovarian, fallopian tube and peritoneal cancer	08 Dec 23								
ID4066 (TA946)	Olaparib	Ovarian, fallopian tube and peritoneal cancer	08 Dec 23								
ID3943 (TA947)	Loncastuximab tesirine	B-cell lymphoma	14 Dec 23								
ID4039 (TA935)	Secukinumab	hidradenitis suppurativa	18 Dec 23								
ID4031 (TA944)	Durvalumab	Biliary tract cancer	20 Dec 23								
ID4021 (TA949)	Belomosedil	Chronic graft vs host disease	21 Dec 23								
ID3920 (TA951)	Abiraterone	Prostate cancer	09 Jan 24								
ID3920 (TA951)	Olaparib	Prostate cancer	09 Jan 24								
ID1342 (TA952)	Talazoparib	Breast cancer	19 Jan 24								
ID6262 (TA878)	Nirmatrelvir/ritonavir	COVID-19	26 Jan 24								
ID4045 (TA954)	Epcoritamab	B-cell lymphoma	01 Feb 24								
ID6307 (TA953)	Fluocinolone acetonide	Chronic diabetic macular oedema	20 Feb 24								
ID1688 (TA950)	Nivolumab	Melanoma	21 Feb 24								
ID4007 (TA958)	Ritlecitinib	Alopecia areata	22 Feb 24								
ID3938 (TA924)	Tirzepatide	Type 2 diabetes	23 Feb 24								
ID3748 (TA959)	Daratumumab	Amyloidosis	28 Feb 24								
ID6191 (TA962)	Olaparib	Ovarian, fallopian tube or peritoneal cancer	28 Feb 24								
ID3876 (TA934)	Foslevodopa-foscarbidopa	Parkinson's disease	29 Feb 24								
ID6184 (TA964)	Cabozantinib	Renal cell carcinoma	11 Mar 24								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6184 (TA964)	Nivolumab	Renal cell carcinoma	11 Mar 24								
ID3968 (TA963)	Dostarlimab	Endometrial cancer	14 Mar 24								
ID6141(TA957)	Momelotinib	Myelofibrosis-related splenomegaly	14 Mar 24								
ID5084 (TA967)	Pembrolizumab	Hodgkin lymphoma	21 Mar 24								

End of Report